Results were similar, although less pronounced in the 2-year cohort based on management to standard of care and medication changes; all PHEN/TPM-ER-treated patients showed reductions in SBP and DBP (see Table S1, Supplemental Digital Content, http://links.lww.com/HJH/A339) [87,92]. At 2 years, there was also a significant net reduction in concomitant antihypertensive medication use in patients treated with PHEN/TPM-ER, whereas placebo-treated patients experienced a net increase in antihypertensive medication use (P = 0.0165 for between-group differences; see Table S1, Supplemental Digital Content, http://links.lww.com/HJH/A339) . The slight mean increases in heart rate vs. baseline with PHEN/TPM-ER treatment observed in the 1-year cohort were still evident after 2 years of treatment, but were not significant compared with placebo (see Table S1, Supplemental Digital Content, http://links.lww.com/HJH/A339) .
Increased myocardial oxygen demand is the putative mechanism by which increased heart rate promotes cardiac ischaemia in patients with macrovascular or microvascular coronary disease . The rate pressure product, defined as the product of heart rate and SBP divided by 1000, is related to myocardial oxygen demand, and was decreased in the placebo group and each of the PHEN/TPM-ER groups in the 1-year cohort (with greatest reductions seen in the PHEN/TPM-ER 7.5/46 dose; Fig. 2c)  and the 2-year cohort (see Table S1, Supplemental Digital Content, http://links.lww.com/HJH/A339) . These data suggest that the mild heart rate increase with PHEN/TPM-ER over 2 years may not increase myocardial oxygen demand.
In patients with dyslipidaemia or hypertension at baseline participating in the 56-week CONQUER study, PHEN/TPM-ER induced significantly greater, dose-related mean percentage weight loss vs. placebo (P < 0.0001), with a greater proportion of PHEN/TPM-ER-treated patients achieving at least 5, 10, and 15% weight loss . PHEN/TPM-ER treatment was associated with significant improvements in serum triglyceride, high-density lipoprotein cholesterol (HDL-C), and non-HDL-C levels vs. placebo (P < 0.05) in patients with dyslipidaemia at week 56, along with a net reduction in lipid-lowering medication use . In patients with hypertension at baseline, PHEN/TPM-ER-treated patients showed significant improvements in BP at week 56 [SBP: −6.9 and −9.1 mmHg for PHEN/TPM-ER 7.5/46 and 15/92, respectively, vs. −4.9 mmHg for placebo (P < 0.05); DBP: −5.2 and −5.8 mmHg for PHEN/TPM-ER 7.5/46 and 15/92, respectively, vs. −3.9 mmHg for placebo (P < 0.05)], as well as a net decrease in antihypertensive medication use (P < 0.0001 for between-group differences) . Similar to the overall CONQUER population, a slight increase in heart rate (0.1 to 1.3 b.p.m.) was observed in the dyslipidaemia and hypertension subgroups [85,86].
In pooled data of hypertensive patients from the two 1-year studies (CONQUER and EQUIP), reductions in SBP and DBP were seen in all PHEN/TPM-ER groups, whereas heart rate was slightly increased in the 7.5/46 and 15/92 dose groups (Table 3) . At endpoint in the 2-year cohort, patients with hypertension at baseline showed reductions in SBP and DBP. Concomitant antihypertensive medication use in PHEN/TPM-ER-treated patients was significantly reduced, compared to a net increase in antihypertensive medication use in the placebo group (P = 0.0012 for between-group differences; see Figure S1, Supplemental Digital Content, http://links.lww.com/HJH/A339) .
Common adverse events in PHEN/TPM-ER clinical trials were paraesthesia, dizziness, dysgeusia, insomnia, constipation, and dry mouth. Adverse events were generally dose-related and mild to moderate in severity, occurring mostly during the titration period [26,84,86–88]. PHEN/TPM-ER contraindications are similar to those of phentermine and topiramate monotherapy (Table 2) [18–20,26,65,66].
Cardiac arrhythmia-related adverse events reported by patients (as defined by mapping to the Medical Dictionary for Regulatory Activities Cardiac Disorders System Organ Class) were palpitations, increased heart rate, and tachycardia, and occurred in between 0.1 and 2.4% of patients (palpitations: 0.8, 0.8, 2.4, and 1.7% for placebo and PHEN/TPM-ER 3.75/23, 7.5/46, and 15/92, respectively; heart rate increased: 0.1, 0.0, 0.4, and 0.8%, respectively; tachycardia: 0.1, 0.4, 0.4, and 0.7%, respectively) . There were low rates of serious adverse events classified as cardiac disorders .
Within the 1-year safety cohort, 752 (19.8%) patients were considered to have low cardiovascular risk, 2498 (65.6%) had moderate cardiovascular risk, and 14.6% were in a high cardiovascular risk category [modified Adult Treatment Panel (ATP) III criteria] . In the 1 and 2-year safety cohorts, the different outcome definitions of major adverse cardiac events (MACEs) each had a hazard ratio (PHEN/TPM-ER vs. placebo) below 1.0, ranging from 0.49 [95% confidence interval (CI) 0.19, 1.25] for US FDA MACE to 0.84 (95% CI 0.26, 2.64) for the traditional MACE composite endpoint (cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke; Table 4) . The traditional MACE composite endpoint (cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke) was incident in 12 of the 4323 patients (5/1742 in the placebo group and 7/2581 in the PHEN/TPM-ER group; Table 4); the wide CI found in the analysis of the traditional MACE composite endpoint indicates that a larger sample is required to sufficiently address this issue . The hazard ratio for the broadest MACE criteria (cardiovascular/neurovascular serious adverse events), which had a total of 43 events (20/1742 in the placebo group and 23/2581 in the PHEN/TPM-ER group), had a 95% CI with an upper bound of 0.98, representing a statistically significant reduction in cardiovascular risk (Table 4) . At this time, there are too few events from clinical trial data to draw firm conclusions about decreases or increases in MACE in patients treated with PHEN/TPM-ER; however, available data do not indicate any increased cardiovascular risk associated with PHEN/TPM-ER. A cardiovascular outcomes trial is planned by the drug's manufacturer, in accordance with one of the US FDA's post-marketing study requirements . The EMA's CHMP has indicated that a long-term cardiovascular outcomes trial would be necessary to support PHEN/TPM-ER centralized approval in Europe . In addition to the planned long-term cardiovascular outcomes trial, future research might beneficially be directed at exploring the effects of PHEN/TPM-ER on surrogate physiologic measures of cardiovascular health, such as endothelial function, and in obese individuals with resistant hypertension.
There is a current unmet need for an effective weight-loss pharmacotherapy that can be used for long term for the many patients unable to attain or to maintain weight loss through dietary interventions and exercise. Given the increased cardiovascular and metabolic risk in this patient population, obesity pharmacotherapies must present minimal unwanted or adverse cardiovascular risks, which if present, should be outweighed by their other cardiovascular-related benefits. The rationale of combining low doses of PHEN/TPM-ER is to minimize side effects while maintaining weight loss efficacy. However, the treatment is not without side effects. For example, the topiramate extended-release component can induce paraesthesia and taste change, likely through carbonic anhydrase inhibition. Topiramate cannot be used by pregnant women due to teratogenic risks. The phentermine component can produce adrenergic symptoms, such as dry mouth. However, it is clinically reassuring that weight loss induced by PHEN/TPM-ER was associated with improved BP through 1 and 2 years of treatment. Although small, usually transient, increases in heart rate were observed in some patients, there were concurrent reductions in BP and rate pressure product, suggesting that, when used in conjunction with lifestyle modifications, PHEN/TPM-ER may represent a safe and effective therapy for the management of obesity in the patient populations studied (those with low-to-intermediate cardiovascular risk). The influences of PHEN/TPM-ER treatment on cardiovascular outcomes are currently being tested in a large multinational trial.
We would like to acknowledge and thank The Lockwood Group for editorial assistance.
Funding for this manuscript was provided by VIVUS, Inc.
J.J. has participated in advisory boards for Boehringer-Ingelheim, Sanofi-Aventis, and Novartis, has been a consultant for Sanofi-Aventis and Novartis, and has received research support from Novartis, Sanofi-Aventis, CVRx, Inc., and Boehringer-Ingelheim. A.A. has been a consultant for Arena Pharmaceuticals, Basic Research, Gelesis, Inc., Doyen Medical Inc., Novo Nordisk, Orexigen Therapeutics Inc., Rhythm Pharmaceuticals, S-Biotek, Twinlab, and VIVUS, Inc. S.E. has received research support for clinical trials from Novartis. K.N. has participated in advisory boards for Medtronic and Boehringer-Ingelheim, has been a consultant for Medtronic, and has received research support for clinical trials for Abbott and Daiichi Sankyo. K.N. has also received honoraria for speakers/chairmanship at meetings for Abbott, Adamed, Astra Zeneca, Bayer, Berlin-Chemie, Boehringer-Ingelheim, Daiichi-Sankyo, Krka, Menarini, Novartis, Pfizer, Polpharma, Sanofi-Aventis, and Servier. W.W.D. is an employee of VIVUS, Inc. N.F. has been a consultant to VIVUS, Inc., and has participated in advisory board(s) for Novo Nordisk, Abbott, and Sanofi-Aventis, is a stockholder of Counterweight plc, and is an employee of UCLH NHS Trust.
Reviewers’ Summary Evaluations Reviewer 1
This review showed that combining low doses of phentermine and topiramate for the treatment of obesity minimized side effects while maintained weight loss efficacy. The side effects were paraesthesia, taste changes and dry mouth.
Weight loss induced by the combination was associated with improved BP through one and two years of treatment. A small, usually transient increase in heart rate was observed. However, reductions in BP and rate pressure product were seen suggesting that when used in conjunction with lifestyle modifications, the combination may represent a safe and effective therapy for the management of obesity. A large multinational trial concerning cardiovascular outcomes is ongoing.
Combination drug treatment based on phentermine and topiramate has been recently approved by the FDA for the treatment of overweight and obesity. The paper by Jordan et al. provides an updated review on the cardiovascular effects of this new therapeutic approach which, along with its significant and sustained weight loss effects, improves triglycerides and HDL cholesterol and significantly decreases blood pressure values throughout the body weight reduction.
The information available so far on the impact the drug has on cardiovascular events (limited at present at the one year follow-up) confirms the favourable effects the drug has on cardiovascular risk.
2. Nguyen T, Lau DC. The obesity
epidemic and its impact on hypertension. Can J Cardiol
3. Jordan J, Yumuk V, Schlaich M, Nilsson PM, Zahorska-Markiewicz B, Grassi G, et al. Joint statement of the European Association for the Study of Obesity
and the European Society of Hypertension: obesity
and difficult to treat arterial hypertension. J Hypertens
4. Gerber Y, Jacobsen SJ, Frye RI, Weston SA, Killian JM, Roger VL. Secular trends in deaths from cardiovascular diseases: a 25-year community study. Circulation
5. Sytkowski PA, Kannel WB, D’Agostino RB. Changes in risk factors and the decline in mortality from CVD. The Framingham Heart Study. N Engl J Med
6. Ford ES, Capewell S. Proportion of the decline in CV mortality disease due to prevention vs. treatment: public health vs. clinical care. Annu Rev Public Health
7. Franklin BA, Cushman M. Recent advances in preventive cardiology and lifestyle medicine. Circulation
8. Stewart ST, Cutler DM, Rosen AB. Forecasting the effects of obesity
and smoking on U.S. life expectancy. N Engl J Med
9. Torgerson JS, Sjostrom L. The Swedish Obese Subjects (SOS) study: rationale and results. Int J Obes Relat Metab Disord
2001; 25 (Suppl 1):S2–S4.
10. Caterson ID, Finer N, Coutinho W, Van Gaal LF, Maggioni AP, Torp-Pedersen C, et al. Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial. Diabetes Obes Metab
11. Wing RR, Lang W, Wadden TA, Safford M, Knowler WC, Bertoni AG, et al. Benefits of modest weight loss in improving cardiovascular risk
factors in overweight and obese individuals with type 2 diabetes. Diabetes Care
12. Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, et al. Task Force Members2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens
13. Coons MJ, Roehrig M, Spring B. The potential of virtual reality technologies to improve adherence to weight loss behaviors. J Diabetes Sci Technol
14. Scheen AJ. The future of obesity
: new drugs versus lifestyle interventions. Expert Opin Investig Drugs
15. Sjöström L, Peltonen M, Jacobson P, Sjöström CD, Karason K, Wedel H, et al. Bariatric surgery and long-term cardiovascular events. J Am Med Assoc
16. Colquitt JL, Picot J, Loveman E, Clegg AJ. Surgery for obesity
. Cochrane Database Syst Rev
17. Greenstein AJ, Wahed AS, Adeniji A, Courcoulas AP, Dakin G, Flum DR, et al. Prevalence of adverse intraoperative events during obesity
surgery and their sequelae. J Am Coll Surg
18. Ionamin. Package insert. Smyrna, GA, USA: UCB, Inc.; 2012.
19. Adipex. Package insert. Sellersville, PA, USA: Teva Pharmaceuticals USA; 2005.
20. Suprenza. Package insert. Cranford, NJ, USA: Akrimax Pharmaceuticals, LLC; 2012.
21. Xenical. Package insert. South San Francisco, CA, USA: Genentech; 2012.
22. Xenical. Patient information leaflet. Shire Park, Welwyn Garden City, UK: Roche Registration Limited; 2012.
23. Alli. Summary of product information. Greenford, Middlesex, UK: Glaxo Group Limited; 2007.
24. Alli. Package insert. Moon Township, PA, USA: GlaxoSmithKline Consumer Healthcare; 2007.
25. Belviq. Package insert. Zofingen, Switzerland: Arena Pharmaceuticals; 2012.
extended-release [package insert]. Mountain View, CA, USA: VIVUS, Inc.; 2013.
27. Derosa G, Maffioli P. Antiobesity drugs: a review about their effects and their safety. Expert Opin Drug Saf
28. Jick H, Vasilakis C, Weinrauch LA, Meier CR, Jick SS, Derby LE. A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation. N Engl J Med
29. Padwal RS, Majumdar SR. Drug treatments for obesity
: orlistat, sibutramine, and rimonabant. Lancet
30. Rich S, Rubin L, Walker AM, Schneeweiss S, Abenhaim L. Anorexigens and pulmonary hypertension in the United States: results from the surveillance of North American pulmonary hypertension. Chest
31. Sachdev M, Miller WC, Ryan T, Jollis JG. Effect of fenfluramine-derivative diet pills on cardiac valves: a meta-analysis of observational studies. Am Heart J
32. Schembre DB, Boynton KK. Appetite-suppressant drugs and primary pulmonary hypertension. N Engl J Med
1997; 336:510–511.[author reply 512–513].
33. Tellier P. Fenfluramines, idiopathic pulmonary primary hypertension and cardiac valve disorders: facts and artifacts. Ann Med Interne (Paris)
34. Topol EJ, Bousser MG, Fox KA, Creager MA, Despres JP, Easton JD, et al. Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. Lancet
35. Torp-Pedersen C, Caterson I, Coutinho W, Finer N, Van Gaal L, Maggioni A, et al. Cardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial. Eur Heart J
36. Kang JG, Park CY. Antiobesity drugs: a review about their effects and safety. Diabetes Metab J
43. Rothman RB, Ayestas MA, Dersch CM, Baumann MH. Aminorex, fenfluramine, and chlorphentermine are serotonin transporter substrates. Implications for primary pulmonary hypertension. Circulation
44. Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll I, Partilla JS. Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse
45. Zolkowska D, Rothman RB, Baumann MH. Amphetamine analogs increase plasma serotonin: implications for cardiac and pulmonary disease. J Pharmacol Exp Ther
46. Birkenfeld AL, Schroeder C, Boschmann M, Tank J, Franke G, Luft FC, et al. Paradoxical effect of sibutramine on autonomic cardiovascular regulation. Circulation
47. Eisenhofer G, Saigusa T, Esler MD, Cox HS, Angus JA, Dorward PK. Central sympathoinhibition and peripheral neuronal uptake blockade after desipramine in rabbits. Am J Physiol
1991; 260 (4 Pt 2):R824–R832.
48. Jordan J, Scholze J, Matiba B, Wirth A, Hauner H, Sharma AM. Influence of sibutramine on blood pressure: evidence from placebo-controlled trials. Int J Obes
49. Schroeder C, Tank J, Boschmann M, Diedrich A, Sharma AM, Biaggioni I, et al. Selective norepinephrine reuptake inhibition as a human model of orthostatic intolerance. Circulation
50. Tank J, Schroeder C, Diedrich A, Szczech E, Haertter S, Sharma AM, et al. Selective impairment in sympathetic vasomotor control with norepinephrine transporter inhibition. Circulation
51. Esler MD, Wallin G, Dorward PK, Eisenhofer G, Westerman R, Meredith I, et al. Effects of desipramine on sympathetic nerve firing and norepinephrine spillover to plasma in humans. Am J Physiol
52. Hendricks EJ, Rothman RB, Greenway FL. How physician obesity
specialists use drugs to treat obesity
. Obesity (Silver Spring)
53. Kang JG, Park CY, Kang JH, Park YW, Park SW. Randomized controlled trial to investigate the effects of a newly developed formulation of phentermine
diffuse-controlled release for obesity
. Diabetes Obes Metab
54. Kim KK, Cho HJ, Kang HC, Youn BB, Lee KR. Effects on weight reduction and safety of short-term phentermine
administration in Korean obese people. Yonsei Med J
55. Munro JF, MacCuish AC, Wilson EM, Duncan LJ. Comparison of continuous and intermittent anorectic therapy in obesity
56. Valle-Jones JC, Brodie NH, O’Hara H, O’Hara J, McGhie RL. A comparative study of phentermine
and diethylpropion in the treatment of obese patients in general practice. Pharmatherapeutica
57. Hendricks EJ, Greenway FL, Westman EC, Gupta AK. Blood pressure and heart rate effects, weight loss and maintenance during long-term phentermine
pharmacotherapy for obesity
. Obesity (Silver Spring)
58. Hendricks EJ, Srisurapanont M, Schmidt SL, Haggard M, Souter S, Mitchell CL, et al. Addiction potential of phentermine
prescribed during long-term treatment of obesity
. Int J Obes (Lond)
59. Center for Disease ControlCardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: U.S. Department of Health and Human Services Interim Public Health Recommendations. MMWR Morb Mortal Wkly Rep
60. Rothman RB, Baumann MH. Serotonergic drugs and valvular heart disease. Expert Opin Drug Saf
61. Whigham LD, Dhurandhar NV, Rahko PS, Atkinson RL. Comparison of combinations of drugs for treatment of obesity
: body weight and echocardiographic status. Int J Obes (Lond)
62. Bang WD, Kim JY, Yu HT, Sung-Soo C, Jang JY, Oh CM, et al. Pulmonary hypertension associated with use of phentermine
. Yonsei Med J
63. Yosefy C, Berman M, Beeri R. Cusp tear in bicuspid aortic valve possibly caused by phentermine
. Int J Cardiol
64. Hendricks EJ, Rothman RB. Re: pulmonary hypertension associated with use of phentermine
? Yonsei Med J
65. Topamax. Package insert. Titusville, NJ, USA: Janssen Pharmaceuticals, Inc.; 2012.
66. Topamax. Package leaflet. High Wycombe, Bucks: Janssen-Cilag Ltd.; 2012.
67. Silberstein SD, Neto W, Schmitt J, Jacobs D. MIGR-001 Study GroupTopiramate in migraine prevention: results of a large controlled trial. Arch Neurol
68. Sugrue MF. Pharmacological and ocular hypotensive properties of topical carbonic anhydrase inhibitors. Prog Retin Eye Res
69. Turenius CI, Htut MM, Prodon DA, Ebersole PL, Ngo PT, Lara RN, et al. GABA(A) receptors in the lateral hypothalamus as mediators of satiety and body weight regulation. Brain Res
70. Xu Y, O’Brien WG 3rd, Lee CC, Myers MG Jr, Tong Q. Role of GABA release from leptin receptor-expressing neurons in body weight regulation. Endocrinology
71. Picard F, Deshaies Y, Lalonde J, Samson P, Richard D. Topiramate
reduces energy and fat gains in lean (Fa/?) and obese (fa/fa) Zucker rats. Obes Res
72. Astrup A, Caterson I, Zelissen P, Guy-Grand B, Carruba M, Levy B, et al. Topiramate
: long-term maintenance of weight loss induced by a low-calorie diet in obese subjects. Obes Res
73. Bray GA, Hollander P, Klein S, Kushner R, Levy B, Fitchet M, Perry BH. A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate
for weight loss in obesity
. Obes Res
74. Rosenstock J, Hollander P, Gadde KM, Sun X, Strauss R, Leung A. OBD-202 Study GroupA randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of topiramate
controlled release in the treatment of obese type 2 diabetic patients. Diabetes Care
75. Stenlof K, Rossner S, Vercruysse F, Kumar A, Fitchet M, Sjostrom L. Topiramate
in the treatment of obese subjects with drug-naive type 2 diabetes. Diabetes Obes Metab
76. Tonstad S, Tykarski A, Weissgarten J, Ivleva A, Levy B, Kumar A, Fitchet M. Efficacy and safety of topiramate
in the treatment of obese subjects with essential hypertension. Am J Cardiol
77. Toplak H, Hamann A, Moore R, Masson E, Gorska M, Vercruysse F, et al. Efficacy and safety of topiramate
in combination with metformin in the treatment of obese subjects with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Int J Obes
78. Wilding J, Van Gaal L, Rissanen A, Vercruysse F, Fitchet M. A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate
in the treatment of obese subjects. Int J Obes Relat Metab Disord
79. Danielsson BR, Lansdell K, Patmore L, Tomson T. Effects of the antiepileptic drugs lamotrigine, topiramate
and gabapentin on hERG potassium currents. Epilepsy Res
80. Lathers CM, Schraeder PL. Clinical pharmacology: drugs as a benefit and/or risk in sudden unexpected death in epilepsy? J Clin Pharmacol
81. Shorvon SD. Safety of topiramate
: adverse events and relationships to dosing. Epilepsia
1996; 37 (Suppl 2):S18–S22.
82. Puscas I, Coltau M, Baican M, Domuta G, Hecht A. Vasodilatory effect of diuretics is dependent on inhibition of vascular smooth muscle carbonic anhydrase by a direct mechanism of action. Drugs Exp Clin Res
83. Puscas I, Gilau L, Coltau M, Pasca R, Domuta G, Baican M, Hecht A. Hypotensive effect of calcium channel blockers is parallel with carbonic anhydrase I inhibition. Clin Pharmacol Ther
84. Allison DB, Gadde KM, Garvey WT, Peterson C, Schwiers ML, Najarian T, et al. Controlled-release phentermine
in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring)
85. Davidson MH, Tonstad S, Oparil S, Schwiers M, Day WW, Bowden CH. Changes in cardiovascular risk
associated with phentermine
extended-release in participants with comorbidities and a body mass index ≥27 kg/m2
. Am J Cardiol
86. Gadde KM, Allison DB, Ryan DH, Peterson CA, Troupin B, Schwiers ML, Day WW. Effects of low-dose, controlled-release, phentermine
combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet
87. Garvey WT, Ryan DH, Look M, Gadde KM, Allison DB, Peterson CA, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine
in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr
88. Jordan J, Troupin BT. Cardiovascular effects and weight loss in three 1-year, double-blind, placebo-controlled clinical trials with extended-release phentermine
in obese patients. Presented at the 22nd Annual Congress of the European Society of Hypertension (ESH). London, UK; April 2012.
89. Jordan J, Astrup A, Day W. Cardiovascular safety of phentermine
alone and in combination with topiramate
. Presented at the 19th Annual European Congress on Obesity
(ECO). Lyon, France; May 2012.
90. Bays H. Phentermine
and their combination for the treatment of adiposopathy (‘sick fat’) and metabolic disease. Expert Rev Cardiovasc Ther
91. Dallas, TX, USA, Brownell KD. The LEARN program for weight management. 10th ed2004; American Health Publishing Company,
93. Davidson M, Bowden CH, Day WW. Weight loss and cardiovascular risk
reduction over 2 years with controlled-release phentermine
. Presented at the 60th Annual Scientific Session and Expo of the American College of Cardiology (ACC). New Orleans; April 2011.
94. White WB. Heart rate and the rate-pressure product as determinants of cardiovascular risk
in patients with hypertension. Am J Hypertens
1999; 12 (2 Pt 2):50S–55S.